Disease Description
Melanoma is considered the most dangerous form of skin cancer. These cancerous growths develop when unrepaired DNA damage to skin cells (most often caused by ultraviolet radiation from sunshine or tanning beds) triggers mutations (genetic defects) that lead the skin cells to multiply rapidly and form malignant tumors. These tumors originate in cells called melanocytes. Melanocytes are the cells responsible for giving our skin their color. Melanomas often resemble moles; some develop from moles. The majority of melanomas are black or brown, but they can also be skin-colored, pink, red, purple, blue or white. Melanoma is caused mainly by intense, occasional UV light exposure (frequently leading to sunburn), especially in those who are genetically predisposed to the disease. [1]
Prevelance
Melanoma is the fifth most common cancer in men and seventh in women in the United States. The number of melanoma cases is increasing faster than for any other type of cancer. Estimates for 2014 are that 76,100 invasive melanomas will be diagnosed in the United States and that melanoma could claim 9710 lives [2].
Current Treatment Options
At present, prevention and early detection are the only effective measures against melanoma. Melanoma basically remains a surgical disease, and excision of thin, biologically early tumors offers the best chance of cure. Despite intensive research, no effective therapies exist for advanced melanoma. Only high-dose IFN -2b has a reproducible benefit in stage II and III patients, but owing to its numerous side effects, modest efficacy, and high cost, it is not used worldwide and is inconsistently used in the United States. For patients with stage IV melanoma, randomized, controlled trials have shown no significant advantage of any specific drug or combination of drugs. Dacarbazine, the only cytotoxic drug approved by the FDA for the treatment of metastatic melanoma, remains the benchmark, but it produces responses of moderate duration and only in a small fraction of the patients. New therapeutic strategies are therefore necessary for the management of melanomas.[3]
Evidence for and the Proposed Mechanism of Cannabinoid Therapeutics
Accumulating recent evidence implicates the endocannabinoid system in the regulation of growth of skin cells. Cannabinoids were also reported to inhibit the growth of melanomas that express cannabinoid receptors (CB1 and CB2) by decreasing growth, proliferation, blood vessel growth and metastasis formation, while increasing cell death. [4]
Groups have studied the potential efficacy of cannabinoids as antitumoral agents against melanoma and showed that these compounds exert a remarkable growth-inhibiting effect on melanoma cells that is evident under various experimental settings (animals with different immune statuses, melanoma cells inoculated at different sites, cannabinoids injected by different routes). Moreover, this is associated with an improvement of various tumor-progression parameters (decreased proliferation and vascularization, increased cell death), as well as with an inhibition of tumor-cell metastatic spreading, one of the clinical hallmarks of advanced melanoma.[5]
Together with the implication of cannabinoid receptors (CB2) in the control of processes such as pain initiation, emesis, and inflammation, opens the attractive possibility of finding cannabinoid-based therapeutic strategies devoid of nondesired psychotropic side effects. Specifically, the antiproliferative effect of cannabinoids reported may set the basis for a new therapeutic approach for the treatment of malignant melanoma.[5]
1. Skin Cancer Foundation. www.skincancer.org/
2. National Cancer Institute. http://seer.cancer.gov/statfacts/html/melan.html
3. Blazquez, C. et al. (2006) Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 20, 2633–2635
4. Pacher, P. et al. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci. Aug 2009; 30(8): 411–420.
5.Blazquez, C. et al. (2006) Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 20, 2633–2635
Recent GBXI News:
May 11, 2023, GBX International Group, Inc., (OTC: GBXI)
GBX International Group, Inc. (OTC:GBXI) Confirms 2023 Strong Revenue Growth Guidance Projections by Combining Each Acquired Operating Company Product Release, Expects Strong Growth Sector by Sector Through its Multiple Product Releases into North American and International Markets
April 21, 2023, GBX International Group, Inc., (OTC: GBXI)
HARVARD Award Winning Entrepreneur, Mr. Raymond C. Dabney Acquires Majority Shareholder Control of GBX International Group, Inc. (OTC: GBXI) Makes More History Bringing CSi-EDP Partner American States University (ASU) as the First Acquisition for its Aggressive Growth Plans
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
Hello Raymond,
Anything new and exciting for to report on our progress? Curious minds want to know! We should start trading soon I would hope...Hello Raymond,
Anything new and exciting for to report on our progress? Curious minds want to know! We should start trading soon I would hope. Always forward my friend
Show more
Hi Raymond,
As a long-standing Loyal Shareholder, I hope that this posting finds you in good health and good spirits. I made my first CBIS purchase...Hi Raymond,
As a long-standing Loyal Shareholder, I hope that this posting finds you in good health and good spirits. I made my first CBIS purchase in Sept 2014 (Dr. Bob was still at CBIS) and I made my last purchase in June 2017; just prior to the Hemp Seizure that F'k-up everything for CBIS going forward.
BUT, on 2017-01-09 CBIS Entered into 1 yr. Research Collaboration Agreement (RCA) with Dana Farber Cancer Institute (DFCI) to Develop Cannabinoid-Based Medications and Associated Delivery Technologies for the Treatment of Cancers.
Then on 2018-01-18 1st Frontiers In Oncology Article: "Nano Particle Drone to Target Lung Cancer with Radio Sensitizers & Cannabis." - KILLING CANCER
And then again on 2018-02-02 CBIS expanded the RCA with DFCI for 5 yrs. (@ $1.8M) to develop Cannabinoid-Based Medications and Associated Delivery Technologies for the Treatment of Cancers. That RCA agreement expired on 2023-02-02.
NOW, On 2023-02-02 the Expanded RCA with DFCI has ended. THE RESULTS ARE NOW KNOWN:
For the $1.8mil investment with DFCI, several Cancer Killing Formulations have been developed.
#1-6 Represents the drug formulations developed by DFCI during the 5yr RCA for treatment of the following cancers:
1. Skin Cancer
2. Breast Cancer
3. Brain Cancer
4. Kaposi's Sarcoma
5. Lung Cancer
6. Pancreatic Cancer
7. CBN Patent Valuation
#7 is the US Patent that was awarded to CBIS which describes the formulation used to treat certain neurological ailments such as ODD, ADD, etc.
On 2023-05-08 it was announced that GBXI signs the first 3 acquisitions for the GBXI Conglomerate (follow link below for details)
finance.yahoo.com/news/gbxi-advances-forward-signs…
Then On 2023-12-13 you posted the following: "GBXI Corporate Filings, Financials, and trading status has been delayed due to change of control filings and approvals. The Company has several options on the list for trading resumption as it pursues its regulatory approvals. The Company is pursuing the fastest path to trading first and will proceed down the list as it moves towards its ultimate goal of bringing all the GBXI conglomerate company shares back trading again.
QUESTION: Where are we toward the completion of this process?? 50% / 75% / 90% ????
--------
Some info that the I have found about a SPAC is as follows:
When does a SPAC become public?
--------------------------------------------
These types of transactions, most commonly where a SPAC acquires or merges with a private company, occur after, often many months or more than a year after, the SPAC has completed its own IPO. Unlike an operating company that becomes public through a traditional IPO, however, a SPAC is a shell company when it becomes public.
Period to consummate the initial business combination.
--------------------------------------------------------------------
A SPAC will typically provide for a two-year period to identify and complete an initial business combination transaction. However, some SPACs have opted for shorter periods, such as 18 months. The SPAC’s governing instruments may permit it to extend that time period. If a SPAC seeks to extend the time period, it may be required to seek shareholder approval. If a SPAC lists its securities on an exchange, it is required to complete an initial business combination within three years of its IPO. IPO proceeds are held in the trust account until a SPAC consummates a business combination or liquidates. If the SPAC is liquidated, shareholders at the time of the liquidation will be entitled to their pro rata share of the aggregate amount then on deposit in the trust account.
On 2023-11-08 an independent entity named Capizate, Inc.; prepared and presented a "Situation Analysis of the GBX International Group" which provided a list of Strengths, Areas of Improvements, and a Cancer Drug Valuation of just one of the drug formulations noted above ($25Mil-$29Mil) - Impressive.
However, here is the list that I have concern for; can't go PUBLIC without being fixed:
Areas for improvement
----------------------------
1. The business documents, agreements, term sheets, engagements are all dated in 2017-2018 and need to be updated.
2. Ownership and control of the intellectual property needs to be defined and confirmed.
3. A similar entity has active registration with California Secretary of State. The Company has a different address than on the Company website and also had a Statement of Info due to the California Secretary of State on 05/10/2023. Registered with the California Secretary of State as a Non-Profit Nonprofit Corporation - CA - Mutual Benefit. This will need to be defined.
QUESTIONS:
---------------
(1) Who's working on updating documentation? What's the % complete?
(2) Who owns and/or controls the CBIS Intellectual Property?
(3) is there another entity out there using the same name as Cannabis Science?
(4) WHERE IS BRINGING CBIS BACK PUBLIC AGAIN ON YOUR LIST OF PRIORITIES?
Thank you Raymond in advance of your response.
Best Regards
Show more
Cannabis Science CEO, Presents …
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2023 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2023
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
Not sure... Show more 11 hours 41 minutes ago